STAT

OCTOBER 4, 2022

A little over a century ago, scientists working in laboratories discovered that microbes were the cause of many epidemics. Once they understood that, they began to put their faith more and more in laboratory science. This major transformation, called the bacteriological revolution, began in the 1880s. During this period, diphtheria was one of the leading causes of death among mostly poor children in New York City.

362

362

PharmaVoice

OCTOBER 4, 2022

In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

265

265

pharmaphorum

OCTOBER 6, 2022

An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public. Originally developed by New Zealand tech company Soul Machines with support of the Qatar Ministry of Health, the first version of the virtual health worker was used to combat misinformation about the pandemic.

Diabetes 140

Diabetes Vaccines 140

PhRMA

OCTOBER 5, 2022

America relies on the U.S. Food & Drug Administration (FDA) to keep pace with the scientific advancements happening every day in labs across the country. That’s why the recently enacted Prescription Drug User Fee Act (PDUFA VII) and Biosimilar User Fee Act (BsUFA III) are both great news for biopharmaceutical innovation and for patients. With these programs reauthorized for another five years, the FDA can continue doing its vital work reviewing medicines.

Biosimilars 121

Biosimilars 121

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

OCTOBER 3, 2022

A Swedish scientist won the 2022 Nobel Prize in medicine or physiology on Monday for his groundbreaking research into the evolutionary history of humankind. Svante Pääbo, of the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, accomplished something widely believed to be impossible: recovering and reading DNA from 40,000-year-old bones.

349

349

PharmaVoice

OCTOBER 3, 2022

In the past, patients entrusted their healthcare providers to provide information about health-related matters.

246

246

Pharma Times

OCTOBER 1, 2022

Data further supports the continued development of FLU-v as a broad-spectrum influenza vaccine

Vaccines 155

Vaccines 155

STAT

OCTOBER 4, 2022

After years spent building a seemingly slapdash set of medical initiatives, Verily seems to have a game plan. The Alphabet life sciences spinout is doubling down on the business of evidence generation , trying to build the tools and technical infrastructure that will help pharma and digital health customers run the next generation of clinical trials.

312

312

PharmaVoice

OCTOBER 7, 2022

Pharma execs share their tips for being a better leader.

265

265

pharmaphorum

OCTOBER 7, 2022

A UK study has found that Merck & Co’s oral COVID-19 therapy Lagevrio was unable to reduce hospitalisations compared to placebo in patients at higher risk from the virus, adding fuel to assertions in some quarters that its authorisation was premature. The 25,000-subject PANORAMIC trial conducted by researchers at Oxford University looked at the addition of a five-day course of Lagevrio (molnupiravir) to standard care in people aged over 50, or adults aged 18 and over with conditions th

Vaccines 116

Vaccines Labelling Hospitals 116

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma Times

OCTOBER 4, 2022

University of Lincoln and the University of Sheffield are researching how DNA could be repaired

153

153

STAT

OCTOBER 6, 2022

The American Revolution had July 4. The allies had D-Day. And now U.S. patients, held down for decades by information hoarders, can rally around a new turning point, October 6, 2022 — the day they got their health data back. Under federal rules taking effect Thursday, health care organizations must give patients unfettered access to their full health records in digital format.

308

308

PharmaVoice

OCTOBER 1, 2022

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

148

148

Pharmaceutical Technology

OCTOBER 6, 2022

Pfizer has acquired all the outstanding shares of the common stock of biopharmaceutical firm Global Blood Therapeutics (GBT) in a deal worth nearly $5.4bn. The total enterprise value comprised debt and the net of cash acquired. With the latest acquisition, GBT became a wholly-owned Pfizer subsidiary. GBT discovers and develops life-changing therapies for ailments with an initial focus on sickle cell disease (SCD).

115

115

Pharma Times

OCTOBER 6, 2022

The Airport Region in Central Germany’ presents itself as an attractive location for the international pharmaceutical industry

130

130

STAT

OCTOBER 6, 2022

The United States is in a (relative) Covid-19 lull, with cases and hospitalizations falling as the wave driven by the BA.5 lineage of the Omicron variant recedes. But as if we needed a portent of an anticipated fall and winter wave , Covid is on the rise in some European countries. What’s different, at least for now, is that there’s not one variant pushing the wave.

Hospitals 300

Hospitals Vaccines 300

PharmaTech

OCTOBER 3, 2022

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

143

143

Pharmaceutical Technology

OCTOBER 5, 2022

In 2010, two patients with end-stage refractory chronic lymphocytic leukaemia (CLL) were administered Novartis’ autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah (tisagenlecleucel), as part of a Phase I trial. In March this year, it was reported that these two patients were still in remission, making this the longest known CLL remission after CAR-T therapy and demonstrating to the industry that long-term remission is indeed possible.

Chemotherapy 111

Chemotherapy Labelling 111

Pharma Times

OCTOBER 4, 2022

Treatment involves adult patients with severe alopecia areata

172

172

STAT

OCTOBER 4, 2022

The press release issued by pharmaceutical companies Eisai and Biogen on Sept. 27 might someday be remembered as the beginning of a revolution in Alzheimer’s diagnosis and treatment. Years and years of failed Alzheimer’s trials created, and then fortified , doubts about whether drugs that attacked amyloid, a brain protein linked to Alzheimer’s disease, were a valid approach to its treatment.

Pharmaceutical Companies 295

Pharmaceutical Companies Pharmaceutical Companies Drug Development 295

pharmaphorum

OCTOBER 3, 2022

Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharma companies’ customer communication methods require reimagining as technology progresses. Kapoor says, now, pharma can learn from the on-demand nature of content distribution that Hollywood utilises and simultaneously prepare for future needs in content delivery. “One of our

Communication 110

Communication 110

PhRMA

OCTOBER 4, 2022

Each first week of October, Americans all across the country take time to reflect on an issue which is increasingly recognized as impacting everyone, whether it be directly as it does me, or indirectly through a family member or friend: mental illness. Mental Illness Awareness Week is an opportunity to raise awareness about the impacts of mental illness and to better understand and educate communities about what it means to face a mental illness, deal with significant moments of stress throughou

108

108

Pharma Times

OCTOBER 7, 2022

The companies will aim to improve treatment for patients with prostate, breast and lung cancer

146

146

STAT

OCTOBER 3, 2022

A biopsy that turns out to have benign results can be a relief. But in some cases, it could also mean a patient whose risk of cancer was low from the start has gone through an unnecessarily invasive procedure. By and large, radiologists recommend that patients whose breast MRI scans raise suspicion of a cancerous growth get a biopsy done. But MRIs often pick up on benign lesions that other mammograms and ultrasound may not.

292

292

Pharmaceutical Technology

OCTOBER 4, 2022

Pfizer has acquired commercial-stage biopharmaceutical firm Biohaven Pharmaceutical for $148.50 for each share or a total consideration of nearly $11.6bn in cash. In May, Pfizer entered a definitive agreement to acquire all outstanding shares of Biohaven which were not previously held by the former. . With the takeover, Biohaven became a wholly-owned Pfizer subsidiary.

106

106

pharmaphorum

OCTOBER 4, 2022

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. AavantiBio, a precision genetic medicine company that was bankrolled by Solid’s rival Sarepta back in 2020, focuses on neuromuscular and cardiac rare diseases.

105

105

PhRMA

OCTOBER 5, 2022

Insurer-imposed barriers like high deductibles and coinsurance shift the cost of life-saving care onto patients. Manufacturers and others have stepped forward to assist patients who face high out-of-pocket costs, using programs like copay coupons to help eligible, commercially insured patients afford their out-of-pocket costs. In fact, the share of patients staying on treatment for one year increased by up to 47% when patients used copay coupons.

105

105

STAT

OCTOBER 4, 2022

Looking for an actually concise explanation of a half-century’s worth of research and arguments about health care spending in the U.S.? You’re in luck: Government budget wonks, against all odds, condensed it down to a single PowerPoint slide. The slide is part of a broader report from the Congressional Budget Office that finds that capping the prices that hospitals, doctors, and other providers charge private health insurers would lower health care prices significantly more than ma

Hospitals 279

Hospitals 279

Pharmaceutical Technology

OCTOBER 4, 2022

The type 2 diabetes (T2D) space recently witnessed a new approval: on 15 September, the European Commission (EC) authorised Eli Lilly’s Mounjaro (tirzepatide) for T2D patients. Mounjaro is a dual gastric inhibitory polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonist. This event is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treated diseases, including obesity.

Diabetes 105

Diabetes 105

pharmaphorum

OCTOBER 4, 2022

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU. The approval brings hope to many, with breast cancer having surpassed lung cancer to become the most commonly diagnosed cancer in the world: there are approximately 2.3 million new cases each year, and each year over 620,000 breast cancer patients will die.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies 102

PhRMA

OCTOBER 6, 2022

The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally funded clinics. The biopharmaceutical industry has long supported this program, but unfortunately, 340B has strayed far from its purpose, with more and more for-profit health care entities using these discounts for themselves.

Drug Pricing 101

Drug Pricing Hospitals 101

STAT

OCTOBER 7, 2022

A Merck pill used to combat Covid-19 failed to demonstrate it can lower the risk of hospitalization compared with a placebo among adults at a higher risk from the disease, according to the results of a large study conducted in the U.K. The preliminary results of the randomized trial, which involved more than 25,000 participants, showed that taking molnupiravir did speed time to recovery by about six days, which means that patients did get some relief.

Hospitals 258

Hospitals 258

Pharmaceutical Technology

OCTOBER 3, 2022

The UK National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option to treat Waldenstrom’s macroglobulinaemia (WM) patients. With the latest development, zanubrutinib became the first WM drug to receive the recommendation for routine National Health Service (NHS) usage in England. The recommendation will also be applicable in Wales and Northern Ireland.

Chemotherapy 105

Chemotherapy 105

pharmaphorum

OCTOBER 6, 2022

Biological systems are hugely complex, with a staggering number of pathways interacting every millisecond. The downstream effects of just one biological change are enormous. So, when a new disease emerges, researchers have a near-impossible task working upstream from symptoms to identify the underlying cause and biological mechanisms causing disease.

Dosage 98

Dosage Compounding Hospitals 98

PhRMA

OCTOBER 1, 2022

A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and medical innovation. I-MAK accuses biopharmaceutical companies of blocking competition and gaming the system by patenting new innovations, when in reality, new patents do not extend old patents, and they do not prevent competitors from launching new products.

99

99